Singapore markets closed
Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,483.40 +5.50 (+0.10%) Dow
39,231.30 +103.50 (+0.26%) Nasdaq
17,829.94 +24.79 (+0.14%) Bitcoin USD
61,974.43 +248.12 (+0.40%) CMC Crypto 200
1,294.74 +28.60 (+2.26%)
PCVX Sep 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:38AM EDT. Market open.
| Previous close | 7.90 |
| Open | 9.58 |
| Bid | 5.50 |
| Ask | 10.00 |
| Strike | 90.00 |
| Expiry date | 2024-09-20 |
| Day's range | 6.50 - 10.02 |
| Contract range | N/A |
| Volume | |
| Open interest | 153 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.